Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
In this report we present an extension of the pooled analysis of the prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I in breast cancer patients. We analyzed a different endpoint, metastasis-free survival (MFS). We checked the consistency of the estimates for uPA and PAI-1 for relapse-free survival (RFS) and MFS exploring possible sources of heterogeneity. Nodal status, the most important prognostic factor for breast cancer, introduced heterogeneity in the uPA/PAI-1 survival analyses, reflecting the interaction between nodal status and uPA/PAI-1. The estimates for uPA and PAI-1 were found to be consistent, even when a different transformation of their values was used. The heterogeneity of the separate data sets decreased if the levels of uPA and PAI-1 were ranked, data sets were pooled, and the analyses corrected for the base model that included all traditional prognostic factors, and stratified by data set. We conclude that uPA and PAI-1 are ready to be used in the clinic to help classify breast cancer patients into high and low risk groups.
Look
Maxime
M
Erasmus MC, Josephine Nefkens Institute, Rm. Be 428, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. m.look@erasmusmc.nl
van Putten
Wim
W
Duffy
Michael
M
Harbeck
Nadia
N
Christensen
Ib Jarle
IJ
Thomssen
Christoph
C
Kates
Ronald
R
Spyratos
Frédérique
F
Fernö
Mårten
M
Eppenberger-Castori
Serenella
S
Fred Sweep
C G J
CG
Ulm
Kurt
K
Peyrat
Jean-Philippe
JP
Martin
Pierre-Marie
PM
Magdelenat
Henri
H
Brünner
Nils
N
Duggan
Catherine
C
Lisboa
Björn W
BW
Bendahl
Pär-Ola
PO
Quillien
Véronique
V
Daver
Alain
A
Ricolleau
Gabriel
G
Meijer-van Gelder
Marion
M
Manders
Peggy
P
Edward Fiets
W
W
Blankenstein
Marinus
M
Broët
Philippe
P
Romain
Sylvie
S
Daxenbichler
Günther
G
Windbichler
Gudrun
G
Cufer
Tanja
T
Borstnar
Simona
S
Kueng
Willy
W
Beex
Louk
L
Klijn
Jan
J
O'Higgins
Nial
N
Eppenberger
Urs
U
Jänicke
Fritz
F
Schmitt
Manfred
M
Foekens
John
J
Bendah
Pär-Ola
PO
D001943:Breast Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D011237:Predictive Value of Tests; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
D017395:Plasminogen Activator Inhibitor 1; D014568:Urokinase-Type Plasminogen Activator